Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 34 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2M17mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTBwMEC1O|Ih|ryPMo\5V2FPT0WU
KASUMI-1NIDXVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfM[GR[UUN3ME2wMlAxQTFzIN88US=>MWDTRW5ITVJ?
HCC2218MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULWV45CUUN3ME2wMlAxQTh5IN88US=>MXzTRW5ITVJ?
KARPAS-45MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\aTWM2OD1yLkCxOlcyKM7:TR?=NHP0bIFUSU6JRWK=
HSC-4NHfjXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjzNZJHUUN3ME2wMlAyPzR6IN88US=>MlPaV2FPT0WU
CHL-1NEDZOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoraTWM2OD1yLkCxPFM6KM7:TR?=MUTTRW5ITVJ?
KY821MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XBbWlEPTB;MD6wNlA3KM7:TR?=MX;TRW5ITVJ?
NCI-N87NFntVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTBwMEK3O|Mh|ryPM{D4THNCVkeHUh?=
DOKNY\LdG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwMEOxPVQh|ryPMl;MV2FPT0WU
DSH1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mne4TWM2OD1yLkCzN|E1KM7:TR?=Mk\iV2FPT0WU
MDA-MB-175-VIINXjRbpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13yb2lEPTB;MD6wN|QyPiEQvF2=Ml;2V2FPT0WU
NCI-H2170NHPFSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTBwMEO3Nlgh|ryPNYLmOlF{W0GQR1XS
BT-474MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnvOZJKSzVyPUCuNFQ6QDZizszNNGe3RZVUSU6JRWK=
EFO-27NWfUTpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjKUlNKSzVyPUCuNFUyQDJizszNNEC1NGNUSU6JRWK=
NCI-H720NEfYeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwMEWzNlUh|ryPM2jKVHNCVkeHUh?=
PC-14M3zBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXKNFRKSzVyPUCuNFU3PjhizszNMWLTRW5ITVJ?
EC-GI-10NXHnbWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEf3WpZKSzVyPUCuNFU6OTJizszNM3znN3NCVkeHUh?=
KYSE-450MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3yzfmlEPTB;MD6wOVk4QCEQvF2=M3HqRXNCVkeHUh?=
BPH-1NIrvPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnudJpKSzVyPUCuNFU6QDhizszNMnTGV2FPT0WU
NCI-H292M1y5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHK5cHVKSzVyPUCuNFYxQSEQvF2=MYDTRW5ITVJ?
H9Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjETWM2OD1yLkC3NVMzKM7:TR?=M3rwS3NCVkeHUh?=
NCI-H526MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nB[2lEPTB;MD6wO|gzOyEQvF2=M4j5S3NCVkeHUh?=
NCI-H1623M3HJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnhbpVzUUN3ME2wMlA5ODJ3IN88US=>MW\TRW5ITVJ?
KYSE-140MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\PTWM2OD1yLkC4N|Mh|ryPNXq0e4lIW0GQR1XS
Ca9-22NVS0S|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXycVFKUUN3ME2wMlA5OzV|IN88US=>MVzTRW5ITVJ?
AU565M3:ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[wUGlEPTB;MD6wPFUxPCEQvF2=MXnTRW5ITVJ?
ZR-75-30MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLtSFhKSzVyPUCuNFk2PDVizszNM4jie3NCVkeHUh?=
NCI-H1770NEXxXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwMUCyPEDPxE1?MljvV2FPT0WU
LB2241-RCCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwMUC4PFQh|ryPM4DqW3NCVkeHUh?=
CAL-39M3rJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\seHVKSzVyPUCuNVE4QTJizszNNXKwWmx[W0GQR1XS
UACC-893MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDhdIlKSzVyPUCuNVE5QDVizszNNV\rfo51W0GQR1XS
LU-65NGrtPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHFfHFKSzVyPUCuNVI3OzNizszNNYflO2pOW0GQR1XS
HNNXP2[WFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLYUWJEUUN3ME2wMlE{ODd5IN88US=>NXLH[INMW0GQR1XS
TI-73MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\RV3lKSzVyPUCuNVQ4OTVizszNNFP3e3NUSU6JRWK=
KU812MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULrb4d5UUN3ME2wMlE2PDV4IN88US=>M4XKdHNCVkeHUh?=
SW13NUDEUHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPs[2tKSzVyPUCuNVYzOTZizszNM3HaUnNCVkeHUh?=
BB30-HNCNULScGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13CbmlEPTB;MD6xOlU4PiEQvF2=MnjTV2FPT0WU
HSC-2MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\nOGlEPTB;MD6xOlg{PyEQvF2=MULTRW5ITVJ?
BV-173MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwMUe1PVYh|ryPNUXRNWVvW0GQR1XS
CAL-27NWjReJFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTzTWM2OD1yLkG3OlM3KM7:TR?=M2i5T3NCVkeHUh?=
SBC-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfieIJKSzVyPUCuNVg6PTlizszNMl\GV2FPT0WU
CAL-33NIPoOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDZTWM2OD1yLkKwNVg1KM7:TR?=MmPWV2FPT0WU
NCI-H209NULBXnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vrWWlEPTB;MD6yNFQ3KM7:TR?=MofjV2FPT0WU
COR-L105NYHxNlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHMNYVKSzVyPUCuNlExQDRizszNMkOyV2FPT0WU
HSC-3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwMkGxPVgh|ryPM1\Ud3NCVkeHUh?=
NCI-H69MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4[5dmlEPTB;MD6yNVQ2OSEQvF2=M1zDdXNCVkeHUh?=
MOLT-13MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTBwMkO5O|Uh|ryPMYjTRW5ITVJ?
ML-2NVK2ZlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7wNHN4UUN3ME2wMlI1QDB{IN88US=>MmTaV2FPT0WU
IGROV-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTBwMkW5OVIh|ryPM1PudHNCVkeHUh?=
TK10MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTDTWM2OD1yLkK2O|M5KM7:TR?=NV:wW|lCW0GQR1XS
EoL-1-cellM{HVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwMk[4PVIh|ryPMVTTRW5ITVJ?
HO-1-N-1NIDuR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXvVGhKSzVyPUCuNlc5PTNizszNNVzKUWZqW0GQR1XS
BHYNWrhbpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XEN2lEPTB;MD6yPFY2PSEQvF2=MlzlV2FPT0WU
LU-139MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknTTWM2OD1yLkOwOVEh|ryPM{XsR3NCVkeHUh?=
23132-87M360d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwM{G5NlMh|ryPM{nLdHNCVkeHUh?=
ACHNNE[yPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUH2Voc6UUN3ME2wMlMyQTl2IN88US=>NGW5XotUSU6JRWK=
DoTc2-4510M4rvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\mTWM2OD1yLkOyNlE6KM7:TR?=MVnTRW5ITVJ?
BB65-RCCM1zKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXKTWM2OD1yLkO0OVk{KM7:TR?=MXzTRW5ITVJ?
HLEM{nGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWqxenNFUUN3ME2wMlM2ODR4IN88US=>NXPHSWxqW0GQR1XS
HCC1419M3XCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TBb2lEPTB;MD6zOlQxQCEQvF2=M33FR3NCVkeHUh?=
A388Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;k[4NKSzVyPUCuN|Y5PTdizszNM3\yWXNCVkeHUh?=
NUGC-3MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXXTWM2OD1yLkO4N|c{KM7:TR?=MlS4V2FPT0WU
KYSE-180NHP0VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnXTWM2OD1yLkO5NFg6KM7:TR?=Mnz5V2FPT0WU
TE-6M1fpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7XTWM2OD1yLkSwNlQ3KM7:TR?=MXXTRW5ITVJ?
A498MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfKXpQ5UUN3ME2wMlQxPjd2IN88US=>NEjWS3JUSU6JRWK=
NCI-H1648MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDWTWM2OD1yLkS0NVgzKM7:TR?=M1fWUnNCVkeHUh?=
DU-145NWCzcnQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrWd2ZKSzVyPUCuOFQ5OzNizszNMnn6V2FPT0WU
CW-2NEXIT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTOTWM2OD1yLkS2PVE1KM7:TR?=NFLuXohUSU6JRWK=
A431NV2wXVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULYUXRNUUN3ME2wMlQ5OjN|IN88US=>NEfFXZBUSU6JRWK=
SASNVmyW3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;sNmlEPTB;MD60PFM6QCEQvF2=NXfNOVNRW0GQR1XS
NCI-H2126NXXtU3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XrdGlEPTB;MD61NVkzPiEQvF2=NYrwXJpZW0GQR1XS
NCI-H358MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4H5R2lEPTB;MD61N|IyKM7:TR?=NYXGRYNvW0GQR1XS
FADUNGjCZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLtTWM2OD1yLkW0OFA1KM7:TR?=MnjiV2FPT0WU
ACNMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnP5TWM2OD1yLkW1NFk1KM7:TR?=NFnYWXNUSU6JRWK=
HCC70MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrGZ|BTUUN3ME2wMlU4PjZzIN88US=>M17Qe3NCVkeHUh?=
NCI-H1838MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLOTWM2OD1yLk[wNlk6KM7:TR?=MXTTRW5ITVJ?
CAL-54NIPiXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLnbW5KSzVyPUCuOlE3OjFizszNNVLuWXJPW0GQR1XS
NCI-H1975NWPSbY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XIPWlEPTB;MD62NVczQCEQvF2=MVLTRW5ITVJ?
COR-L88NHPLXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTBwNkSxNVMh|ryPMV7TRW5ITVJ?
CTV-1NIDSdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTBwNkSzPVIh|ryPMmT6V2FPT0WU
EW-18NYj3bpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLiTWM2OD1yLk[4Olk5KM7:TR?=MW\TRW5ITVJ?
HCC1806NVfLcGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPsTWM2OD1yLk[5OlY3KM7:TR?=NXz2UlljW0GQR1XS
HuP-T4M4OwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nHbmlEPTB;MD62PVc3KM7:TR?=M3S3NnNCVkeHUh?=
MDA-MB-361MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvhTWM2OD1yLkeyOlYzKM7:TR?=NHHiWJRUSU6JRWK=
NCI-H1573M3j5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXxTWM2OD1yLkezOlMh|ryPMoXIV2FPT0WU
KU-19-19NFm1XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7KRollUUN3ME2wMlc4PDZ2IN88US=>MV\TRW5ITVJ?
COLO-678MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwOEC4N|Qh|ryPMVTTRW5ITVJ?
C-33-ANFrNOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjLTWM2OD1yLkixNlk4KM7:TR?=NYLvclVlW0GQR1XS
Calu-3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHTe2pUUUN3ME2wMlgyPDN2IN88US=>NEL4TFZUSU6JRWK=
AGSNV7qXYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrTNY1KSzVyPUCuPFM3PDhizszNMV3TRW5ITVJ?
SCC-25Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7zdFBiUUN3ME2wMlg1OTdzIN88US=>NXPLXVF4W0GQR1XS
JVM-2MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HsbWlEPTB;MD64PFI6QSEQvF2=M1uyVnNCVkeHUh?=
HCE-TNXe3b3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXnTWM2OD1yLki4OFI5KM7:TR?=M1H5OnNCVkeHUh?=
ES4NFzBcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLlZmRKSzVyPUCuPVc5OzZizszNM{\GNHNCVkeHUh?=
EKVXNHK1dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPVR2pKSzVyPUGuNFExPjRizszNMWTTRW5ITVJ?
D-542MGM2rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLkcFNKSzVyPUGuNFExPjRizszNNIrXV2pUSU6JRWK=
SW1116MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjoTWM2OD1zLkCxNlg4KM7:TR?=MWfTRW5ITVJ?
5637MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\ne2lEPTB;MT6wNVUyKM7:TR?=MYTTRW5ITVJ?
HT-1376NGr5XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPIXWJ[UUN3ME2xMlAyPTF|IN88US=>NI\wNnVUSU6JRWK=
NB69NX3MSWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XLW2lEPTB;MT6wNlk1PSEQvF2=M3PYTXNCVkeHUh?=
YKG-1M{npdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTFwMEW0NVkh|ryPNUH6XIl{W0GQR1XS
EW-3MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;yTWM2OD1zLkC3PFg{KM7:TR?=Mme5V2FPT0WU
GCIYNVKyb|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTFwMEixNFQh|ryPNWfTWnB1W0GQR1XS
SK-MES-1M37adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDxZ2FKSzVyPUGuNVE1QDdizszNNITQe5JUSU6JRWK=
PANC-08-13NYmxUGk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTFwMU[0NVYh|ryPMlH3V2FPT0WU
SK-NEP-1M2nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fpRWlEPTB;MT6xO|UyOyEQvF2=M3LRXXNCVkeHUh?=
SW954M4ey[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwMkCyNVQh|ryPMljFV2FPT0WU
NCI-SNU-5M1PLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfBdVVMUUN3ME2xMlI{QSEQvF2=MojuV2FPT0WU
SW48NV65bpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\UTWM2OD1zLkK1OFMzKM7:TR?=Mn3lV2FPT0WU
HT-3NXT4dG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfqfpdnUUN3ME2xMlI5PzV|IN88US=>NHrJRodUSU6JRWK=
ETK-1MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHJTWM2OD1zLkO3OFU3KM7:TR?=MUjTRW5ITVJ?
SCC-15NIPKdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwM{m0OVEh|ryPMXnTRW5ITVJ?
DU-4475MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPoSoN5UUN3ME2xMlQxOTJzIN88US=>MUDTRW5ITVJ?
NB5NXzBdYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\WTWM2OD1zLkSxN|E4KM7:TR?=NILTdIZUSU6JRWK=
CFPAC-1MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVn0d3hZUUN3ME2xMlQzPDl|IN88US=>NWXW[JlWW0GQR1XS
NCI-H630NWnOVmVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFwNEW1PFIh|ryPNUP5bplEW0GQR1XS
NCI-H82MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTFwNUSwNFYh|ryPMk\BV2FPT0WU
ECC10MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3YTWM2OD1zLkW1N|Y6KM7:TR?=NFTP[WFUSU6JRWK=
K5NWDIPW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnsVmlKSzVyPUGuOVg{PTdizszNMY\TRW5ITVJ?
ME-180NVq0UXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELicFlKSzVyPUGuOlExQTZizszNM3XIWXNCVkeHUh?=
KYSE-410MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L2TmlEPTB;MT62OVY4OiEQvF2=Mn3kV2FPT0WU
G-401NUXMOndrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknZTWM2OD1zLk[3OFE{KM7:TR?=MVTTRW5ITVJ?
TGBC24TKBM1zabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrBRpU3UUN3ME2xMlY5OjNizszNM4TlSHNCVkeHUh?=
Detroit562MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFwN{CxOVIh|ryPMVvTRW5ITVJ?
OE19MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlW3TWM2OD1zLkexOVEzKM7:TR?=NUjYbYttW0GQR1XS
CAKI-1M{nZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M121bmlEPTB;MT63PFIyOSEQvF2=MnjrV2FPT0WU
TE-12MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jHSmlEPTB;MT64NFQyPCEQvF2=MYrTRW5ITVJ?
NCI-H1666NXfRflZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1znc2lEPTB;MT64NFk1QCEQvF2=MWfTRW5ITVJ?
TE-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLYfnhKSzVyPUGuPFE1PzVizszNNFK0TJBUSU6JRWK=
CAL-12TMkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUi5eW5bUUN3ME2xMlg5QTR3IN88US=>MknEV2FPT0WU
TE-8NF;UZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[1[WlEPTB;MT65NVM4PyEQvF2=NGXJOYZUSU6JRWK=
KYSE-270M4\pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTJwMEK3N|Ih|ryPNXPLNpZqW0GQR1XS
GMS-10NIGwTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTJwMEO1NVch|ryPNYrxd3ZIW0GQR1XS
A2780NWDuWWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvtWFA6UUN3ME2yMlA3Ojl2IN88US=>MVXTRW5ITVJ?
OMC-1M1vpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\pUopYUUN3ME2yMlA5OTZ7IN88US=>NIfvOlVUSU6JRWK=
LoVoNUfZdIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXLTWM2OD1{LkGwO|k4KM7:TR?=MWXTRW5ITVJ?
PANC-03-27M{PZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJwMU[2N|Eh|ryPNIXKUlNUSU6JRWK=
MDA-MB-157M{nPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmThTWM2OD1{LkKxPFI5KM7:TR?=MW\TRW5ITVJ?
CaR-1NFn2OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:wTWM2OD1{LkK4NlgyKM7:TR?=MUPTRW5ITVJ?
769-PM1zrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLBXFFKSzVyPUKuNlkxOzdizszNMlPLV2FPT0WU
NB7MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHRdJpKSzVyPUKuNlk3PzZizszNMnj0V2FPT0WU
MKN7MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTOTWM2OD1{LkO1N|M2KM7:TR?=MoHMV2FPT0WU
NCI-H1048NIn6VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7ITWM2OD1{LkS5NVU5KM7:TR?=MoraV2FPT0WU
RCM-1NVvLZ5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJwNUK5N|gh|ryPMknXV2FPT0WU
HT55MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzOTWM2OD1{LkW3N|gh|ryPMXfTRW5ITVJ?
HCC1569M3fPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkOzTWM2OD1{LkW4Nlk4KM7:TR?=NI\R[XhUSU6JRWK=
LXF-289NWjHU48zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELweIZKSzVyPUKuOlM2PjVizszNNWTobIdwW0GQR1XS
OVCAR-3MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfnWFA3UUN3ME2yMlY4OTZ5IN88US=>NXLK[mtKW0GQR1XS
TE-10MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rSbWlEPTB;Mj62PFA4QCEQvF2=MUXTRW5ITVJ?
SNU-C2BM4TpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEGwOJZKSzVyPUKuOlg3OTZizszNNHHSWnFUSU6JRWK=
LB1047-RCCMmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLrbW5KSzVyPUKuO|Q5QDhizszNM4LaNnNCVkeHUh?=
SN12CMoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle1TWM2OD1{LkmxPVY1KM7:TR?=MYLTRW5ITVJ?
786-0NFfjb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\1bopKSzVyPUOuNFY1ODhizszNMlvBV2FPT0WU
HT-29M2DUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTNwMEezNFkh|ryPMnSxV2FPT0WU
RPMI-7951MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfrTWM2OD1|LkC3OVkh|ryPMYnTRW5ITVJ?
NBsusSRNYTXRnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwMUiyOVQh|ryPNVq5T|JiW0GQR1XS
NKM-1M{HFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTNwMUi3OFQh|ryPM2PLVXNCVkeHUh?=
Capan-2NFznXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXOTWM2OD1|LkS2PFc2KM7:TR?=MWPTRW5ITVJ?
MKN1MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXsTWM2OD1|LkS3NVA5KM7:TR?=MnGwV2FPT0WU
OAW-42NVfyVHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTNwNUCwNlYh|ryPM1[0XnNCVkeHUh?=
SKG-IIIaM4DMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mke0TWM2OD1|LkWyNlM4KM7:TR?=NFHiVZdUSU6JRWK=
no-11NXvQS3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjIR2VCUUN3ME2zMlU{PTZ2IN88US=>NE\kSJJUSU6JRWK=
NYNFzwSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDlTWM2OD1|LkWzOlU2KM7:TR?=MoLjV2FPT0WU
HEC-1Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjaS4hKSzVyPUOuOVg6PSEQvF2=NXuye3RlW0GQR1XS
NCI-H441NXHPcYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2L4ZWlEPTB;Mz61PVg1OSEQvF2=MYLTRW5ITVJ?
NCI-H2009MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTNwNkGyNVYh|ryPM2XEZnNCVkeHUh?=
T47DMonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfrWZNKSzVyPUOuOlIzOTdizszNMlrqV2FPT0WU
SNU-449NHrE[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHMZ3lKSzVyPUOuOlU5OjZizszNNEjUVZZUSU6JRWK=
NCI-SNU-1MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGq5W4hKSzVyPUOuOlk4OzVizszNMoHLV2FPT0WU
BT-20NH\POXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrmZpNKSzVyPUOuOlk4QTVizszNMWHTRW5ITVJ?
LS-123MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNwN{SyPFQh|ryPM1jqc3NCVkeHUh?=
8305CNWPlbJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzXSGhKSzVyPUOuO|U6OTFizszNNGjyeItUSU6JRWK=
OCUB-MMlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTNwN{[xPFch|ryPNF3LXWRUSU6JRWK=
KOSC-2MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MomzTWM2OD1|LkizOFUyKM7:TR?=NWjWVXpvW0GQR1XS
NCI-H1693M{HNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfkO2EzUUN3ME2zMlg1OThzIN88US=>NI\kOlhUSU6JRWK=
TE-9NWHGZYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTNwOESzPFIh|ryPNGrNNFBUSU6JRWK=
MV-4-11MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nzS2lEPTB;Mz64O|k6PCEQvF2=NEDPT|dUSU6JRWK=
GAMGMoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XRRWlEPTB;Mz65NVMyPCEQvF2=NYfPeI1MW0GQR1XS
KNS-62NXvzW|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3nToRXUUN3ME2zMlk1PzNzIN88US=>NEK4SW9USU6JRWK=
MC116NFm0bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M324VmlEPTB;Mz65OVQ5QSEQvF2=MoXSV2FPT0WU
647-VNXnMOJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfSb5FKSzVyPUOuPVg1PTJizszNNEm3eVFUSU6JRWK=
U-87-MGMmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTRwMUC0PFEh|ryPMoC0V2FPT0WU
RPMI-8226MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7WUIo6UUN3ME20MlEyPjNzIN88US=>NHXINlRUSU6JRWK=
SW1417NVLxbpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTRwMUKxOFch|ryPNHvWOnJUSU6JRWK=
LAMA-84NWr3[ZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M324bWlEPTB;ND6xO|AzKM7:TR?=NITPc|dUSU6JRWK=
LS-513M{XRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTRwM{GyNVch|ryPNHKxVJBUSU6JRWK=
KLEMn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTRwNEC4NVkh|ryPM3rSNnNCVkeHUh?=
HCT-116MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVr2fFZYUUN3ME20MlQyODB5IN88US=>M4L2NHNCVkeHUh?=
EPLC-272HNUTQWWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O0XmlEPTB;ND60NVU{OyEQvF2=NX3r[oV5W0GQR1XS
KS-1NYnxW4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjZTHBKSzVyPUSuOVA5QDlizszNNFHEN2RUSU6JRWK=
HT-1197NHn0NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTRTWM2OD12LkWyOlY6KM7:TR?=M3TYZXNCVkeHUh?=
LCLC-97TM1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTRwNUO2PFYh|ryPM1;OfXNCVkeHUh?=
ES5NV74W|FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHOUmhKSzVyPUSuPFM4OjNizszNMUnTRW5ITVJ?
CTB-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH0TWM2OD12Lki0PFgh|ryPNFLnT2RUSU6JRWK=
HL-60MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHZdohLUUN3ME20Mlg3PjFzIN88US=>MlzQV2FPT0WU
VM-CUB-1M{mzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTRwOE[4NVkh|ryPMX3TRW5ITVJ?
MEG-01M2TmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTRwOUm0NFMh|ryPNEewbXJUSU6JRWK=
KYSE-520M3\NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTVwMkC4N|kh|ryPNHzi[3BUSU6JRWK=
HuO-3N1NYHkUJQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTVwMkSwOFMh|ryPMX3TRW5ITVJ?
SW620MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvjTWM2OD13LkK0PVY1KM7:TR?=M4OxbHNCVkeHUh?=
U031NULBNVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jpbWlEPTB;NT6yOVQzPCEQvF2=NIPSUVNUSU6JRWK=
TE-5NFrnOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\BNmJbUUN3ME21MlQxQDVizszNNH7zfVZUSU6JRWK=
NCI-H747MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT6TWM2OD13LkSyOFczKM7:TR?=M1nrXHNCVkeHUh?=
MG-63MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TxOGlEPTB;NT60PFc3OiEQvF2=MoH5V2FPT0WU
HC-1NEO0dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTVwNUG4N|kh|ryPMWXTRW5ITVJ?
HCC2998NEnxVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTVwNUK2NVUh|ryPM2ThRnNCVkeHUh?=
NTERA-S-cl-D1NH7PW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fQZWlEPTB;NT61OFU{PyEQvF2=M3zjTXNCVkeHUh?=
KINGS-1MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2C4eGlEPTB;NT62NFk1PCEQvF2=NYP4VHk{W0GQR1XS
D-423MGNFW1b2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzTNVZwUUN3ME21MlYyPzB3IN88US=>M3u1XXNCVkeHUh?=
SW962Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfUTWM2OD13Lk[yNFMzKM7:TR?=M{T0N3NCVkeHUh?=
LOXIMVIMl7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1P6SmlEPTB;NT62N|g4OyEQvF2=NEnSfVFUSU6JRWK=
LS-411NNHj3W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfLTWM2OD13Lke5OFQyKM7:TR?=Mln3V2FPT0WU
NCI-H2291MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHnTWM2OD13Lkm4PVQ{KM7:TR?=MoTPV2FPT0WU
A549MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTZwMUK1OVMh|ryPNF3nZY9USU6JRWK=
LS-1034M3zhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3r3VGlEPTB;Nj6yNFcxPiEQvF2=NUj2TGdMW0GQR1XS
NB14NELHZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLRTWM2OD14LkSzPFM3KM7:TR?=NIjoTXVUSU6JRWK=
NCI-H1299MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXhTWM2OD14Lk[zNVcyKM7:TR?=NYfk[3Q5W0GQR1XS
BT-549NYPVWlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7GTWM2OD14Lk[2PFg6KM7:TR?=MYPTRW5ITVJ?
J-RT3-T3-5NVfzTnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\YWIhKSzVyPU[uPFY6KM7:TR?=NXfZSlVyW0GQR1XS
SW756NYHvbJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjuW|N2UUN3ME22MlkyOTd4IN88US=>MUPTRW5ITVJ?
DJM-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DyfGlEPTB;Nj65NlAyOiEQvF2=MX7TRW5ITVJ?
GP5dNViyN3hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\kTWM2OD14Lkm3N|k1KM7:TR?=NVXSTmZtW0GQR1XS
MOLT-4NFHocIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWT4TXRzUUN3ME23MlAzOTN3IN88US=>MnLjV2FPT0WU
NCI-H28M1\vdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:5TWM2OD15LkG2OFA2KM7:TR?=M3S0dnNCVkeHUh?=
MN-60M1HtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTdwMkiwPFkh|ryPMoLCV2FPT0WU
RMG-IM3niNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXMSolKSzVyPUeuN|kzQTZizszNMmL4V2FPT0WU
COLO-800NVTPfXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjlV5VSUUN3ME23MlQyPDR4IN88US=>NFLYOWxUSU6JRWK=
DBMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[yTWM2OD15Lk[xNFA2KM7:TR?=MoPjV2FPT0WU
Ca-SkiM{faNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHjVnRKSzVyPUeuOlQzPTlizszNNX\KWWdtW0GQR1XS
HELNWnmU2VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTdwN{GyNFMh|ryPNXvTdmMzW0GQR1XS
NH-12MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3TWFJrUUN3ME23MlczQDB6IN88US=>M3\Ne3NCVkeHUh?=
LB373-MEL-DMoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU[4VFdkUUN3ME23Mlc3PzdzIN88US=>Mmi0V2FPT0WU
SW900M1[zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfYc2NKSzVyPUeuPFIyOjFizszNNYfpTohrW0GQR1XS
JVM-3NVGxSmdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnzV5hLUUN3ME23Mlg6PTl7IN88US=>M{j3SnNCVkeHUh?=
OAW-28MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmGzTWM2OD15Lkm0OVc5KM7:TR?=MljjV2FPT0WU
KURAMOCHINHrhUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4H2WmlEPTB;Nz65OFgyOSEQvF2=NFjTNIlUSU6JRWK=
BE-13NETYflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXW4RVVPUUN3ME23Mlk5OTF{IN88US=>M2PhO3NCVkeHUh?=
VMRC-RCZNI\ET|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPpRYxMUUN3ME24MlAyPjl5IN88US=>NVrnV49XW0GQR1XS
NCI-H727NX;6S2hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\1b5ZKSzVyPUiuNVA1OiEQvF2=MWDTRW5ITVJ?
SW1710NHHPe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHG1O5dKSzVyPUiuNVg2OTVizszNNULxNpR4W0GQR1XS
D-502MGMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRThwMkmyPFIh|ryPM1viUXNCVkeHUh?=
NCI-H1993MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXYUHpKSzVyPUiuN|M3OzFizszNMWDTRW5ITVJ?
SCC-4M1\KNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLaSpZKSzVyPUiuOFQxPTlizszNMVHTRW5ITVJ?
HAL-01NVHmcI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjWTWM2OD16LkWxPVEh|ryPNW\1TnhpW0GQR1XS
GT3TKBNIj3R|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRThwNke5OlQh|ryPNF3ORYNUSU6JRWK=
SK-OV-3MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHP3c5lKSzVyPUiuO|E{OjlizszNMXTTRW5ITVJ?
COLO-829Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPoTWM2OD16LkiwPVc3KM7:TR?=NV7HR2RWW0GQR1XS
OCI-AML2M4X3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLkTWM2OD16Lkm1OFgyKM7:TR?=NUD0e5YzW0GQR1XS
OS-RC-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTlwMEKxPUDPxE1?M2CyPXNCVkeHUh?=
BFTC-909NXPtWGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13tdWlEPTB;OT6wOlc6QSEQvF2=NWTRXolHW0GQR1XS
EW-11Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXQTWM2OD17LkG3OlU{KM7:TR?=NEPtO4RUSU6JRWK=
HCE-4NEn3bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTlwMkG1OVgh|ryPM2fS[XNCVkeHUh?=
BALL-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTlwMkG5NFch|ryPMnq0V2FPT0WU
SF539M1HafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLz[XNIUUN3ME25MlI{PTZ{IN88US=>MnLXV2FPT0WU
CAMA-1M{HsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnhWo0xUUN3ME25MlI5OTJ6IN88US=>MmnMV2FPT0WU
C32NGftNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXvZVIxUUN3ME25MlM{ODZ2IN88US=>NGS1Z2FUSU6JRWK=
NCI-H1703NIDSU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfuOmxKSzVyPUmuN|Q{PzVizszNNGnLXlFUSU6JRWK=
NCI-H1650NVfuPYxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjGXIRKSzVyPUmuOlA6PDZizszNMnfTV2FPT0WU
NCI-H1563NYXLW4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTZ[ItDUUN3ME25Mlc3ODNzIN88US=>NGLJV3FUSU6JRWK=
CAL-85-1NXvxSHBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LHO2lEPTB;OT64O|M5OyEQvF2=M2XDZ3NCVkeHUh?=
UM-UC-3NWrDUWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULjV2V3UUN3ME25Mlk2ODNizszNNX6zS3hvW0GQR1XS
BxPC-3M2ni[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3WwRmlEPTB;MUCuNFk4OiEQvF2=M2Wx[nNCVkeHUh?=
MHH-PREB-1NH;LZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfxTWM2OD1zMD6xPVk6KM7:TR?=NHnDfIFUSU6JRWK=
DELNWr5eJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml61TWM2OD1zMD6zPVQ3KM7:TR?=MojvV2FPT0WU
HuCCT1M1ywbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFyLk[wN|Mh|ryPMn;xV2FPT0WU
OVCAR-4NWTUbFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFyLki4N|Uh|ryPNYHhWHQ3W0GQR1XS
CAL-72M3rnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\RdWlEPTB;MUCuPVM6OSEQvF2=MYLTRW5ITVJ?
HCC1954MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LpcGlEPTB;MUGuNFc2PCEQvF2=NH\rTIFUSU6JRWK=
EFO-21MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWOyS25KUUN3ME2xNU4yODR3IN88US=>NULHdYNYW0GQR1XS
FTC-133M{fYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPYR5JRUUN3ME2xNU4yPDB5IN88US=>NH7RTlJUSU6JRWK=
SK-MEL-24MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVj1T5hZUUN3ME2xNU4zOzZ4IN88US=>MX;TRW5ITVJ?
UACC-62MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXHXW9EUUN3ME2xNU4zOzZ6IN88US=>M1G1PXNCVkeHUh?=
NCI-H650Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonSTWM2OD1zMT6yOFE5KM7:TR?=Mn60V2FPT0WU
ALL-POMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVziSlJUUUN3ME2xNU4zPTF{IN88US=>MlfMV2FPT0WU
T84MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\nTWM2OD1zMT6zPVA4KM7:TR?=MkTMV2FPT0WU
IST-MEL1M2Tw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLUVZpKSzVyPUGxMlQ2PTlizszNM2fofHNCVkeHUh?=
SW626MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTFzLkW3OVUh|ryPMormV2FPT0WU
RPMI-2650MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFzLkW4PFUh|ryPMYTTRW5ITVJ?
MC-IXCMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfDZphKSzVyPUGxMlY4OjhizszNNGXUZnZUSU6JRWK=
HOP-62NIfEbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HEcGlEPTB;MUGuOlc3PCEQvF2=NIfEUmlUSU6JRWK=
NOS-1M4XpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LJNmlEPTB;MUGuO|ExQSEQvF2=NYnoWHNkW0GQR1XS
SW1573NXvRfVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi5U2RKSzVyPUGxMlczQTVizszNMV\TRW5ITVJ?
WM-115NUHiWXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETSe5lKSzVyPUGxMlc2QDhizszNNVPzS2NtW0GQR1XS
HuO9M1rOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1O2XWlEPTB;MUGuPFc4PCEQvF2=M2DPNHNCVkeHUh?=
YAPCNXP0[mo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFzLkmyOVkh|ryPMofTV2FPT0WU
MDA-MB-453M2XZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWD5RZd3UUN3ME2xNU46PTF3IN88US=>NHfPPWpUSU6JRWK=
NCI-H596NIL3SoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHvTWM2OD1zMj6wN|Y6KM7:TR?=MV;TRW5ITVJ?
A172NFXmRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e5OWlEPTB;MUKuNFc6QCEQvF2=M1zTPHNCVkeHUh?=
RS4-11NEnCO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG5eFBxUUN3ME2xNk4yPzJ3IN88US=>Mlm2V2FPT0WU
HCC1937MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPKWVhEUUN3ME2xNk44PTZ2IN88US=>MkS2V2FPT0WU
SW837NEXhbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF{LkmwNlgh|ryPNX72ZXV{W0GQR1XS
NMC-G1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFznNFBKSzVyPUGyMlkzOzRizszNMl\BV2FPT0WU
PFSK-1MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTF|LkC2JO69VQ>?MXzTRW5ITVJ?
DBTRG-05MGMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;UdmlEPTB;MUOuNFY{OiEQvF2=MXnTRW5ITVJ?
SK-UT-1Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPPOIN2UUN3ME2xN{4yODh|IN88US=>MVrTRW5ITVJ?
OVCAR-5M2GwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfnOFRKSzVyPUGzMlE2QTNizszNMVfTRW5ITVJ?
8505CNV:wWJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF|LkKwOlch|ryPNIK3NpRUSU6JRWK=
SK-MEL-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnzfHRQUUN3ME2xN{44OTN3IN88US=>MUHTRW5ITVJ?
LK-2Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTF|Lke2N|kh|ryPM2XTPXNCVkeHUh?=
OE33NIGzZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPoVmRKSzVyPUGzMlc5PiEQvF2=NELYXW1USU6JRWK=
Ramos-2G6-4C10MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvxTWM2OD1zND6wNlAzKM7:TR?=Mki0V2FPT0WU
EW-13NUT0RY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTF2LkCzOVIh|ryPMXnTRW5ITVJ?
NCI-H1793M376d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF2LkKwPFch|ryPMn[5V2FPT0WU
BHT-101M3fsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWD3PFN4UUN3ME2xOE4zPDFizszNM1HSZ3NCVkeHUh?=
RKONX\tSHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoH2TWM2OD1zND61NFc2KM7:TR?=NGTkVXZUSU6JRWK=
NEC8MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTHUnVuUUN3ME2xOE42PDd{IN88US=>NH21S|JUSU6JRWK=
PANC-10-05NWHNZ|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTF2Lk[yOFch|ryPNX;vRoN{W0GQR1XS
NCI-H2030NHfOS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37mfWlEPTB;MUSuOlQ1QCEQvF2=NWjjZ5V1W0GQR1XS
C2BBe1NHXZbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHOyUmZKSzVyPUG0Mlc3PCEQvF2=NH3aNWZUSU6JRWK=
EM-2Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF2Lki1O|Yh|ryPMnK4V2FPT0WU
HCC1395MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTQTWM2OD1zND65N|M5KM7:TR?=NWq1SpJvW0GQR1XS
A2058MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYexNng{UUN3ME2xOU4xPDB7IN88US=>NEXL[odUSU6JRWK=
SW1463MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnpTWM2OD1zNT6wOFg2KM7:TR?=MnrkV2FPT0WU
J82MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjjZYNKSzVyPUG1MlA2PyEQvF2=MoLKV2FPT0WU
CAL-120NGXpVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nHPGlEPTB;MUWuNVQ1PyEQvF2=MX;TRW5ITVJ?
COLO-824NF3XOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\UTWM2OD1zNT6xOVc6KM7:TR?=M1L1NHNCVkeHUh?=
LNCaP-Clone-FGCNGTkd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln4TWM2OD1zNT60NlQ5KM7:TR?=MV7TRW5ITVJ?
CP66-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3P0RWlEPTB;MUWuOFY5QCEQvF2=NXXuOVBGW0GQR1XS
OC-314NV\JPIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDFT|ZHUUN3ME2xOU41PzF2IN88US=>M3jFZXNCVkeHUh?=
OVCAR-8NGmw[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTF3Lki4OlEh|ryPNY\oTm9VW0GQR1XS
MFE-280M4L3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUX4OXpwUUN3ME2xOk4xPDh6IN88US=>MlzsV2FPT0WU
MHH-NB-11NV7jTWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTF4LkC4N|kh|ryPNWfUUWoyW0GQR1XS
SW1990MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnVTWM2OD1zNj6xO|U2KM7:TR?=NGXQeXpUSU6JRWK=
U-266NHm3RmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTjTWM2OD1zNj6yNlk6KM7:TR?=NF\RcWhUSU6JRWK=
MFM-223MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkSzTWM2OD1zNj6zPVY2KM7:TR?=M2XDeHNCVkeHUh?=
L-363NVv5[olYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{C2[GlEPTB;MU[uOFU4PyEQvF2=M{fzSHNCVkeHUh?=
MCF7NGe2TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37DPGlEPTB;MU[uOFczOyEQvF2=MnHaV2FPT0WU
SK-MEL-3M1;BPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTF4LkS3PFch|ryPM{H6NnNCVkeHUh?=
HHMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVizO2R5UUN3ME2xOk42OTZ{IN88US=>M2jzfXNCVkeHUh?=
no-10M2OwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3PfIFKSzVyPUG2MlY{PDNizszNMYjTRW5ITVJ?
HuP-T3M1PiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULmelk3UUN3ME2xOk43PTd4IN88US=>M4i1XnNCVkeHUh?=
QIMR-WILMmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHkcYdKSzVyPUG2MlcyODVizszNNXf6V5prW0GQR1XS
NCI-H1092M{[3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLGc5dKSzVyPUG2Mlg{OTZizszNNY\WUpdDW0GQR1XS
MZ2-MELM2r1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTF4Lki0NFMh|ryPNIHqNHJUSU6JRWK=
ES3M3HWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF4LkmxN|Qh|ryPMlq4V2FPT0WU
COLO-684NVGyb5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrSTWM2OD1zNj65OFc4KM7:TR?=MYTTRW5ITVJ?
NCI-H661M3XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD1V3ZKSzVyPUG2Mlk3QTRizszNMYTTRW5ITVJ?
CP50-MEL-BNWfzOmhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTF5LkCzOFMh|ryPNYDnZ456W0GQR1XS
NCI-H2405MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;ne|NJUUN3ME2xO{4yQTd2IN88US=>NWrXe|RDW0GQR1XS
U-2-OSMmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2r0TGlEPTB;MUeuOVMxPyEQvF2=NI\GPZRUSU6JRWK=
RERF-LC-MSMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXSTWM2OD1zNz61OVA5KM7:TR?=M2PmfXNCVkeHUh?=
NCI-H2342MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF5LkW1O{DPxE1?MoXJV2FPT0WU
ES8NIntepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LlSmlEPTB;MUeuOlA5PyEQvF2=MorNV2FPT0WU
MOLT-16MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TwR2lEPTB;MUeuPFk{PCEQvF2=NHTETJhUSU6JRWK=
RH-18NXiwSVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHYdJRkUUN3ME2xPE4xODN3IN88US=>MXzTRW5ITVJ?
D-283MEDNYnmU|BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTF6LkCwPFgh|ryPNGjUNYlUSU6JRWK=
RCC10RGBNELIdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPUTWM2OD1zOD6wOVU6KM7:TR?=M4nEb3NCVkeHUh?=
NCI-H1437MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF6LkG2OFEh|ryPNE\QOIJUSU6JRWK=
SW982MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTF6LkK2O|Eh|ryPMUHTRW5ITVJ?
IST-MES1MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{m4bWlEPTB;MUiuOFQzQCEQvF2=MUPTRW5ITVJ?
A704NW\YZYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\6PWlEPTB;MUiuOFc2OyEQvF2=MoXZV2FPT0WU
ESS-1MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jtZWlEPTB;MUiuOVIxPSEQvF2=NVLQe2RIW0GQR1XS
SCHNIHaXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LmdGlEPTB;MUiuOlQ2PiEQvF2=Mkj4V2FPT0WU
COLO-320-HSRNHzoZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTF6Lke0OkDPxE1?NE\FNZhUSU6JRWK=
Mo-TMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF6LkiyNFQh|ryPM3\KeHNCVkeHUh?=
Saos-2M1XTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknhTWM2OD1zOT6xNVYzKM7:TR?=NEHsfpJUSU6JRWK=
SW684NV7VZnpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzDNmFKSzVyPUG5MlE{OjZizszNMnjRV2FPT0WU
KMOE-2M3LwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fvcWlEPTB;MUmuNlI1OiEQvF2=NVrGVY4zW0GQR1XS
MMAC-SFNFzFO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vCW2lEPTB;MUmuNlYxPyEQvF2=MofjV2FPT0WU
JARMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXvTWM2OD1zOT6yPVkh|ryPMnvMV2FPT0WU
SK-MEL-28M3LFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX35Z3hkUUN3ME2xPU4{OzZ|IN88US=>NHnYRmVUSU6JRWK=
KNS-81-FDMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7VdJdKSzVyPUG5MlU1PjhizszNMWjTRW5ITVJ?
ES7NHPIenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPEbYRKSzVyPUG5MlYzQTJizszNMWnTRW5ITVJ?
AsPC-1NILYSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkCwTWM2OD1zOT62OFcyKM7:TR?=NEnHe45USU6JRWK=
NCI-H1155MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXyzXZNFUUN3ME2xPU44OjN6IN88US=>MlX1V2FPT0WU
KYSE-510NVO2S41FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY[2V4k{UUN3ME2xPU45PzR6IN88US=>MYHTRW5ITVJ?
ES1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTF7LkmyNVMh|ryPMVjTRW5ITVJ?
PC-3MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f6d2lEPTB;MUmuPVYxPCEQvF2=M3nnPHNCVkeHUh?=
GCTM1X6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXO3[YdHUUN3ME2yNE4{ODJ4IN88US=>MXXTRW5ITVJ?
KARPAS-299NILUR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PRTGlEPTB;MkCuN|QzOiEQvF2=M4CzPXNCVkeHUh?=
DOHH-2Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljqTWM2OD1{MD61OFY{KM7:TR?=MXHTRW5ITVJ?
COLO-741MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnTeZVKSzVyPUKwMlY3KM7:TR?=Mn72V2FPT0WU
NCI-H1395MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jQTmlEPTB;MkCuOlY6PyEQvF2=NHnN[Y9USU6JRWK=
HCC1187NXvqcYdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfwZmRKSzVyPUKwMlY4OzRizszNMXnTRW5ITVJ?
BeckerMkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXP5VWlvUUN3ME2yNE44OjBzIN88US=>MVvTRW5ITVJ?
LU-134-AM2G4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3KVm9KSzVyPUKxMlExOjZizszNMXLTRW5ITVJ?
MKN45M3O1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mne3TWM2OD1{MT6xOVUyKM7:TR?=NIDySYRUSU6JRWK=
LC-2-adMkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D2dmlEPTB;MkGuNlczQSEQvF2=MkPHV2FPT0WU
EW-24NYnv[lRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTOTWM2OD1{MT6zPVQ2KM7:TR?=MmTvV2FPT0WU
SK-N-ASNXzQOFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPsfYxYUUN3ME2yNU45Ojd4IN88US=>M2K3RnNCVkeHUh?=
NCI-H2052MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzNPGhKSzVyPUKxMlg6PjNizszNM3P2V3NCVkeHUh?=
A4-FukMofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTJ{LkG0NVkh|ryPM4XidHNCVkeHUh?=
NB10MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XHd2lEPTB;MkKuNlM4OSEQvF2=NY\WT|dFW0GQR1XS
CHP-212MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3FTWM2OD1{Mj6zNlIzKM7:TR?=M2XpfXNCVkeHUh?=
KM12MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LTT2lEPTB;MkKuN|U3KM7:TR?=M3q3THNCVkeHUh?=
JEG-3MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljHTWM2OD1{Mj6zO|gh|ryPNFHmXXFUSU6JRWK=
LN-405MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJ{LkW5NVMh|ryPM4WxXXNCVkeHUh?=
HCT-15Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;3[WlEPTB;MkKuO|Q1OSEQvF2=NWnFfZdmW0GQR1XS
MLMANGnJSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfiTWM2OD1{Mj63OFch|ryPNFf4NmxUSU6JRWK=
GI-1MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\CTXlKSzVyPUKyMlc3PThizszNNIPZS29USU6JRWK=
RT-112NG[yUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTJ{Lki2NVYh|ryPM17VTXNCVkeHUh?=
MPP-89M1G4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXSNoVKSzVyPUKyMlg3PjFizszNMl\VV2FPT0WU
A3-KAWMnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ|LkGwNFMh|ryPMonYV2FPT0WU
KALS-1NF\nc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJ|LkG0NVQh|ryPMULTRW5ITVJ?
SF126NYrTSnBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vOe2lEPTB;MkOuOlkzPCEQvF2=NWLtSJVoW0GQR1XS
SiHaMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\3So9KSzVyPUKzMlk{OjdizszNM1PPZnNCVkeHUh?=
MDA-MB-415MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTJ|Lkm0PVkh|ryPNUDvRVE3W0GQR1XS
DaoyM{fZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfrVnZKSzVyPUK0MlEzPiEQvF2=M4KzVXNCVkeHUh?=
COR-L23NVOxRllJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;YWYRKSzVyPUK0MlE4PjdizszNM3\MdHNCVkeHUh?=
KG-1NVHkbZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHOTWM2OD1{ND6xPVI5KM7:TR?=NHLGU3JUSU6JRWK=
L-428M1rWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\MTWM2OD1{ND61O|kyKM7:TR?=MkjQV2FPT0WU
NCI-H520MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrRPWVYUUN3ME2yOE45QDZzIN88US=>MXPTRW5ITVJ?
COLO-792NVPubXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\m[GdKSzVyPUK1MlI4OzJizszNMXfTRW5ITVJ?
NB12MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ux[GlEPTB;MkWuNlk1PyEQvF2=NVuxb4NDW0GQR1XS
GAKMk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vtUGlEPTB;MkWuNlk3OyEQvF2=MVfTRW5ITVJ?
SW780MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTrTm5KSzVyPUK1MlMzPjRizszNM3uxPXNCVkeHUh?=
GB-1NEHFeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorOTWM2OD1{NT60NFY6KM7:TR?=MY\TRW5ITVJ?
P12-ICHIKAWAMmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrnfXhKSzVyPUK1MlQ4QDVizszNNVrPdpVEW0GQR1XS
NCI-H1651M4nwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfqO|dQUUN3ME2yOU42QTdizszNNF[2[4NUSU6JRWK=
KE-37M4TDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M373VmlEPTB;MkWuO|MyPSEQvF2=MWTTRW5ITVJ?
CCRF-CEMNX7zU5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXJTWM2OD1{NT65Olch|ryPMkGwV2FPT0WU
SF295NWq3VnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjNT4VKSzVyPUK2MlA1OjVizszNNYjkRpZZW0GQR1XS
G-361NFjxfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGe2eJpKSzVyPUK2MlExOjdizszNMUnTRW5ITVJ?
HOP-92M2H2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[5TWlEPTB;Mk[uNVIzPiEQvF2=NVnMOIdRW0GQR1XS
UMC-11MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkm3TWM2OD1{Nj60OVE1KM7:TR?=MlfwV2FPT0WU
IST-SL1NEfDfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu2fHNKSzVyPUK2MlY2QTFizszNNV;wfJR4W0GQR1XS
TE-11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTSbnZ7UUN3ME2yOk44PzV{IN88US=>MYLTRW5ITVJ?
NCI-H1304MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfmTWM2OD1{Nj65NVA5KM7:TR?=NVT6dFNsW0GQR1XS
SJSA-1M2L2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH6TW1KSzVyPUK3MlAyPzZizszNNHPEeJJUSU6JRWK=
BCPAPNHjPb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy0dph5UUN3ME2yO{4yOzdizszNMoftV2FPT0WU
HTC-C3MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\BNGlEPTB;MkeuNlU3OSEQvF2=MXfTRW5ITVJ?
EW-16M{Lpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXXNlUyUUN3ME2yO{4zQTR5IN88US=>NYjs[Ws3W0GQR1XS
HT-144NH\yR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjoTWM2OD1{Nz60NFMzKM7:TR?=Mlj2V2FPT0WU
MHH-ES-1NVToV4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTJ5LkS0OFch|ryPNXrZXlROW0GQR1XS
T98GNInIfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HUWWlEPTB;MkeuOVg1PiEQvF2=MUTTRW5ITVJ?
RPMI-8866M{joVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnOZoF4UUN3ME2yO{44PTZ{IN88US=>M3zuVnNCVkeHUh?=
BENNUjST2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2e3eGlEPTB;MkeuPFUyPyEQvF2=Ml:3V2FPT0WU
MDA-MB-231M1e3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnL0TWM2OD1{OD6yO|k2KM7:TR?=MYrTRW5ITVJ?
HuH-7MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfITWM2OD1{OD60NFI5KM7:TR?=NFzhT|hUSU6JRWK=
SK-N-FIMoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWr3XolmUUN3ME2yPE41OzNizszNMn\wV2FPT0WU
AN3-CAMlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfMTWM2OD1{OD60N|k2KM7:TR?=NUi3fWIzW0GQR1XS
EGI-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjvTWM2OD1{OD61PVI5KM7:TR?=M1;KcHNCVkeHUh?=
697MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJ6Lk[zN|Eh|ryPNF2ydIhUSU6JRWK=
TCCSUPMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXZTWM2OD1{OD62OFE5KM7:TR?=MWnTRW5ITVJ?
GR-STNWLsSmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4H6OWlEPTB;MkiuOlY6PiEQvF2=NFjFTpNUSU6JRWK=
SK-N-DZNU\iV3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvj[IJlUUN3ME2yPE43QDh3IN88US=>MXLTRW5ITVJ?
MIA-PaCa-2NXvCZXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrUb|FKSzVyPUK4Mlc6PTlizszNM2m0cnNCVkeHUh?=
IGR-1Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3hTIl3UUN3ME2yPE45QDd2IN88US=>MmPBV2FPT0WU
BFTC-905NF[wT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJ7LkK3NFUh|ryPNFvncWtUSU6JRWK=
NCI-H1581MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DoXWlEPTB;MkmuN|E1PSEQvF2=NEW0VYtUSU6JRWK=
RDMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjUcJlKSzVyPUK5MlUzOzNizszNNES5WG5USU6JRWK=
SF268NULxZmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy1WZNRUUN3ME2yPU42QTNzIN88US=>M1XzVXNCVkeHUh?=
SHP-77MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLpR3JFUUN3ME2yPU43OTh{IN88US=>MonkV2FPT0WU
D-566MGMoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPWSXVKSzVyPUK5Mlk{QTNizszNNG\XXJlUSU6JRWK=
TGBC1TKBM3Twdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDwcGRQUUN3ME2zNE4yOjN6IN88US=>MoLDV2FPT0WU
MEL-HOMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTNyLkG0NlMh|ryPMXTTRW5ITVJ?
SJRH30M2i4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG4S4JKUUN3ME2zNE4zOTB6IN88US=>Mmn1V2FPT0WU
D-336MGM1PSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLPTWM2OD1|MD6yPFkzKM7:TR?=NXPxW2sxW0GQR1XS
C3AMlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIGyc|NKSzVyPUOwMlI6OjdizszNNGPzTpJUSU6JRWK=
Calu-6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[5TWM2OD1|MD6yPVY{KM7:TR?=NU[wXHRoW0GQR1XS
MZ1-PCMkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3kTWM2OD1|MD6zPVMh|ryPM2DVWXNCVkeHUh?=
KYSE-70MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jtcGlEPTB;M{CuOVEyPCEQvF2=M4rmPHNCVkeHUh?=
CAPAN-1M{jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:yc2VHUUN3ME2zNE42OThzIN88US=>NIiz[XhUSU6JRWK=
DK-MGNYPuc2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTNyLkW0OVYh|ryPNEjWVllUSU6JRWK=
SK-HEP-1Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTNyLk[zNlYh|ryPMonGV2FPT0WU
MS-1MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXHR3ZNUUN3ME2zNE45QDh7IN88US=>NWjyb2JpW0GQR1XS
GI-ME-NMoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfPXlZTUUN3ME2zNU4xPTdzIN88US=>MoriV2FPT0WU
NCI-H510AMnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XxXWlEPTB;M{GuOFAxPiEQvF2=M4TKXnNCVkeHUh?=
NB17NFzoPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j4VWlEPTB;M{GuOVE5PSEQvF2=M4nINHNCVkeHUh?=
639-VNX32U2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTNzLkWyOFMh|ryPNUfxdpBoW0GQR1XS
CAL-51NETRUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTNzLkW2Olch|ryPM1LwZ3NCVkeHUh?=
HGC-27NUjSWm9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXCVVhuUUN3ME2zNU42QDd|IN88US=>MWfTRW5ITVJ?
GOTOMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTNzLki1NFYh|ryPM33uSnNCVkeHUh?=
ChaGo-K-1NH2wRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfoNGVKSzVyPUOyMlAxPyEQvF2=NXnNNlVFW0GQR1XS
RO82-W-1NXPsR3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDHd2hKSzVyPUOyMlE3ODRizszNMWLTRW5ITVJ?
SH-4M3TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIr1[ndKSzVyPUOyMlE5PThizszNNEHxN2JUSU6JRWK=
A204M2Pt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljTTWM2OD1|Mj61NFY6KM7:TR?=M2Lhe3NCVkeHUh?=
DMS-273NWHOT2RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7sOZNOUUN3ME2zNk42OzJ{IN88US=>NWnPU2UzW0GQR1XS
KGNNEe5bXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17PeGlEPTB;M{KuOlM{KM7:TR?=MV\TRW5ITVJ?
SK-MEL-2M{PibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTN{Lk[1Nlch|ryPM3vwXXNCVkeHUh?=
NCI-H2228MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTJTWM2OD1|Mj62OlAzKM7:TR?=NVzuXmJRW0GQR1XS
MKN28NVvJRo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;oT5N[UUN3ME2zNk44QDN6IN88US=>M3TlS3NCVkeHUh?=
H-EMC-SSNX:5OIxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jKOmlEPTB;M{KuPVY4QCEQvF2=M4fZWHNCVkeHUh?=
ATN-1NW\Le3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LLUGlEPTB;M{OuNVQyPiEQvF2=M1K0UnNCVkeHUh?=
D-263MGMlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTN|LkizO|gh|ryPNGe4[HVUSU6JRWK=
LU-135MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\sTWM2OD1|Mz64PFI6KM7:TR?=M2jHWHNCVkeHUh?=
C8166NWHJSmhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPiS2RuUUN3ME2zN{45QDV2IN88US=>NXLBTJFYW0GQR1XS
T-24MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLWW2pZUUN3ME2zOE4xOjB3IN88US=>MmnyV2FPT0WU
MewoM{nEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTN2LkGzOFkh|ryPM3G1TXNCVkeHUh?=
22RV1M3XDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmP6TWM2OD1|ND6xO|U1KM7:TR?=MYPTRW5ITVJ?
KM-H2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nIbWlEPTB;M{SuNVc4QSEQvF2=MmDGV2FPT0WU
NCI-H2122MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTN2LkO0O|Eh|ryPM2rVNHNCVkeHUh?=
ABC-1Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\YUHBKSzVyPUO0MlM3QTNizszNMmD0V2FPT0WU
NCI-H1355Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4X4U2lEPTB;M{SuN|g5QSEQvF2=NXvvO49VW0GQR1XS
NOMO-1NV;xdZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjhbmFnUUN3ME2zOE42PzB|IN88US=>NUXq[lNNW0GQR1XS
MZ7-melMn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD6TWM2OD1|ND62OFg4KM7:TR?=MljSV2FPT0WU
NCI-H810M1rVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTN2LkeyO|gh|ryPMn;BV2FPT0WU
D-392MGM2nlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nqNGlEPTB;M{WuNFU3PSEQvF2=Mo\xV2FPT0WU
LB771-HNCNXHXelEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX0SnpKSzVyPUO1MlE3PThizszNMlvWV2FPT0WU
COLO-679NY\pZmVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7H[VdKSzVyPUO1MlM5QCEQvF2=M3zWXXNCVkeHUh?=
SK-PN-DWMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPLTINKSzVyPUO1MlQ{PjlizszNMWnTRW5ITVJ?
VA-ES-BJM{HCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTYTWM2OD1|NT60OlQ6KM7:TR?=MnH5V2FPT0WU
KNS-42MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIm5OVBKSzVyPUO1MlU5OjZizszNNX;LfY0yW0GQR1XS
RVH-421M{fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTN3Lke2OFUh|ryPNVz5NVFuW0GQR1XS
P30-OHKM{CzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTN3Lki3OVIh|ryPM1m5UXNCVkeHUh?=
G-402M2nMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrQbY9KSzVyPUO1Mlk5PjdizszNMUfTRW5ITVJ?
S-117NGXiWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi4TWM2OD1|Nj6zNFA5KM7:TR?=M4PRNHNCVkeHUh?=
RXF393NV\6RXNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn2yTWM2OD1|Nj6zO|g2KM7:TR?=Ml70V2FPT0WU
LCLC-103HMkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnq3TWM2OD1|Nj63PFA{KM7:TR?=MVzTRW5ITVJ?
U-118-MGM4\Bd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXsTWM2OD1|Nj64PFQ4KM7:TR?=NUHLXWNoW0GQR1XS
8-MG-BAMoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TyR2lEPTB;M{[uPVQ5OyEQvF2=M4\Eb3NCVkeHUh?=
MFH-inoMorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HKVmlEPTB;M{euN|M4OSEQvF2=MW\TRW5ITVJ?
NCI-H23Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEK4XFlKSzVyPUO3MlQyQTZizszNMV7TRW5ITVJ?
NCI-H446MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fZ[GlEPTB;M{euOFg3OiEQvF2=M2XXXHNCVkeHUh?=
LU-99ANIjjbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NISzVIdKSzVyPUO3MlU4OzFizszNNV3OSIcxW0GQR1XS
KP-N-YNMmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TZXmlEPTB;M{euOlE6PSEQvF2=MlqwV2FPT0WU
SCC-9NXLIVoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7mNJJvUUN3ME2zO{44QDN6IN88US=>NEi0V5NUSU6JRWK=
EFM-19NHfBc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTN5Lke5Olch|ryPM4\G[nNCVkeHUh?=
A427MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LScGlEPTB;M{euPVExPyEQvF2=NH\HZWNUSU6JRWK=
LB831-BLCM3uyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3j1NGlEPTB;M{iuOlA{QSEQvF2=MlftV2FPT0WU
HOSMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXi3dpNZUUN3ME2zPU43Ojd|IN88US=>NGDUVFZUSU6JRWK=
LAN-6NW\ZO3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDCTWM2OD12MD6wNVEzKM7:TR?=MVPTRW5ITVJ?
U251M3fjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTRyLkSwOVQh|ryPNV21VG5tW0GQR1XS
SNU-387MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;mU2lEPTB;NECuOFU2OyEQvF2=NVHVcGJoW0GQR1XS
DMS-79NIrPVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K4PWlEPTB;NECuOVg5QSEQvF2=NHrXWpNUSU6JRWK=
SK-LU-1NIfOO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;uPWlKUUN3ME20NE43PTZ6IN88US=>NHLQe2JUSU6JRWK=
HTNXPBU3Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFK4SW5KSzVyPUSwMlY3OzlizszNNILk[4ZUSU6JRWK=
KP-N-YSMnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIKxOmhKSzVyPUSwMlY4PjhizszNMlHlV2FPT0WU
DMS-114MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvIRYpKSzVyPUSwMlg{PzRizszNNULUd3ZoW0GQR1XS
HUTU-80MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofmTWM2OD12MT6wOVY6KM7:TR?=NXXHd4tmW0GQR1XS
ONS-76MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjjfmxzUUN3ME20NU41PzB7IN88US=>NXThOmNRW0GQR1XS
A673MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{n4eGlEPTB;NEGuOVE2PyEQvF2=NHrjO4lUSU6JRWK=
HPAF-IIMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\GO2lEPTB;NEGuOlcxQSEQvF2=MkO3V2FPT0WU
UACC-257MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfjS3ZKSzVyPUSxMlc{PjlizszNMnHxV2FPT0WU
EW-22Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTRzLki2PVch|ryPMWDTRW5ITVJ?
NCI-H1755MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTRzLki3NlUh|ryPNVLVWodkW0GQR1XS
KYSE-150NYHJXJVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLwOoF1UUN3ME20Nk4yPzh{IN88US=>NVTWcHd6W0GQR1XS
CGTH-W-1NF22[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTR{LkS5OVUh|ryPMofOV2FPT0WU
NB13NYXNV5I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nOe2lEPTB;NEKuOlIyPyEQvF2=M3O5R3NCVkeHUh?=
SW872MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIT2UXVKSzVyPUSyMlY{OzFizszNMnrYV2FPT0WU
KP-4MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTR{Lki4N|Ih|ryPMmDLV2FPT0WU
HCC38M4Oyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7tTWM2OD12Mj65OlE5KM7:TR?=NF3zfWZUSU6JRWK=
BB49-HNCMmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTR|LkKzOVYh|ryPMljMV2FPT0WU
CAL-62M2H4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV30RW4zUUN3ME20N{41ODJ6IN88US=>Ml7wV2FPT0WU
NCI-H2029MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFX2NHpKSzVyPUSzMlU2QDFizszNMX7TRW5ITVJ?
M14Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3H1fGlEPTB;NESuNVM{OiEQvF2=NHr2WGJUSU6JRWK=
COLO-680NNH3mRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTR2LkOzPUDPxE1?M{jvXnNCVkeHUh?=
Hs-578-TM3XuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rY[mlEPTB;NEWuNFI6PCEQvF2=MkC1V2FPT0WU
MSTO-211HMne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPYT3RKSzVyPUS1Mlk1QDJizszNNWfXfJJ3W0GQR1XS
EW-1NHPuNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPO[IFKSzVyPUS1Mlk3QDlizszNNX31bGpHW0GQR1XS
SW948MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe3TWM2OD12Nj60OFYzKM7:TR?=NUXNbI8{W0GQR1XS
NCI-H460NFrCXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTR4LkWyN{DPxE1?MV3TRW5ITVJ?
CAS-1NGDpSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPHTWM2OD12Nj63O|AyKM7:TR?=M2foZ3NCVkeHUh?=
TGBC11TKBNVe3fZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTR5LkG3O|ch|ryPM2HoeXNCVkeHUh?=
HD-MY-ZMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zYSWlEPTB;NEiuO|g3KM7:TR?=MXjTRW5ITVJ?
NCI-H226NV64[21CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTR7Lke3PFUh|ryPM1G3eXNCVkeHUh?=
PA-1NEC2R|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTR7LkizN|Uh|ryPMkXpV2FPT0WU
LB2518-MELM4nwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTR7Lki3NlMh|ryPNH70fYRUSU6JRWK=
A101DMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\pTWM2OD12OT65OFI2KM7:TR?=NFy1OHRUSU6JRWK=
NCI-H2087NIXwc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTTWnRJUUN3ME20PU46Pjh{IN88US=>NEnFZndUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-18)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Not yet recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2
NCT02501603 Not yet recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University March 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Customer Product Validation(3)


Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method CEER assay
Cell Lines H460/A549/RFU cell lines
Concentrations 0-10 μM
Incubation Time 4 h
Results This data showed that a potent dose-dependent inhibition of the HER1 and HER2 pathways in the HCC827 cells was observed by treatment with BIBW-2992. Other HER1 and/or HER2 pathway-activated cell lines, H1975 and H1650, were likewise had these pathway activations blocked by the treatment with BIBW-2992.

Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Afatinib (BIBW2992) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results BIBW2992 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us